High doses of ready-to-use anticoagulants reduce the risk of death in patients with moderately ill COVID-19

Graphical abstraction. Credit: DOI: 10.1136 / bmj.n2400

High-dose, inexpensive, globally available anticoagulants reduce the risk of death in inpatients with moderate illness to COVID-19, a new study led by St. Michael’s Hospital suggests I am.

Released today BMJThe international RAPID trial compared the effects of high-dose heparin with prophylactic low-dose in patients with moderate COVID-19 and elevated d-dimer levels admitted to the hospital.Heparin is universally used blood Thinner that prevents the formation of blood clots. D-dimer is a protein fragment produced when a blood clot dissolves in the bloodstream. Elevated D-dimer levels indicate an increased risk of blood clots.

The researchers studied 465 patients in hospitals around the world, and although the therapeutic dose of heparin was not associated with a significant reduction in the main outcome of the study, which is a composite of death, Mechanical ventilation Or admission to Intensive careHeparin administration reduced all causes of death in moderately ill COVID-19 patients admitted to the hospital by 78%.

“Our study confirms that therapeutic heparin is beneficial to patients in the COVID-19 ward, but other studies may be harmful to patients infected with heparin. It has been suggested that there is. Critical care“. Dr. Peter Uni, director of the Center for Applied Health Research in St. Michael’s and co-leader of the research, said.

The therapeutic dose of heparin is Deep vein thrombosis Or pulmonary embolism, prophylactic or lower doses are used for patients admitted to the internal medicine ward to prevent blood clotting during hospitalization.

Several trials have considered the use of anticoagulants in patients with COVID-19. This is because the virus causes inflammation and coagulation of blood vessels, contributing to serious illness and death. Dr. Michel Schorzberg, Head of Hematology Oncology, Director of the St. Michael’s Coagulation Institute, and co-leader of the study, said the study will help change treatment guidelines for COVID-19 patients. I hope that.

“This is a once-in-a-million opportunity —Heparin It’s cheap, it’s available all over the world, and it exists for everyone. hospital Pharmacy cabinets are now an opportunity to quickly reuse medicines available around the world, “she said.

In particular, she said treatment could make a difference in areas where the availability or scope of vaccines continues to be limited.

Dr. Sholzberg, Dr. Jüni, and an international group of researchers want to learn more from the data by further analyzing it and addressing new questions. They are also considering reviewing patient outcomes to understand whether these treatments reduce the likelihood of long-term COVID.

Early anticoagulant therapy that has been shown to reduce mortality in patients with moderately ill COVID-19

For more information:
Michelle Sholzberg et al, Effectiveness of therapeutic heparin vs. prophylactic heparin for death, ventilator, or admission to the intensive care unit in patients with moderate illness of covid-19 admitted to the hospital: rapid randomization Clinical trials, BMJ (2021). DOI: 10.1136 / bmj.n2400

Quote: Out-of-the-box, high-dose blood diluent reduces the risk of death in patients with moderately ill COVID-19 (October 15, 2021). -blood-thinner-death.html

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

High doses of ready-to-use anticoagulants reduce the risk of death in patients with moderately ill COVID-19

Source link High doses of ready-to-use anticoagulants reduce the risk of death in patients with moderately ill COVID-19

Show More

Related Articles

Back to top button